Case study: Dr. Srinivasan is a senior scientist working for a reputed biotechnology company known for its cutting-edge research in pharmaceuticals.
Identify the stakeholders and the ethical issues, weigh the realistic options, and defend one course with concrete steps; each printed sub-part (a), (b), (c) must be answered on its own.
Common trap: Weak answers only say no to the shortcuts. A top answer treats each shortcut (data, consent, patents) on its own, offers a lawful way to speed up, and grounds part (c) in the Nuremberg Code, Helsinki and India's 2019 trial rules.
SyllabusCase Studies on above issues. (Public/Civil service values and Ethics in Public administration: ethical concerns and dilemmas in government and private institutions; laws, rules, regulations and conscience as sources of ethical guidance; accountability and ethical governance; corporate governance.)
The case
Dr. Srinivasan is a senior scientist working for a reputed biotechnology company known for its cutting-edge research in pharmaceuticals. Dr. Srinivasan is heading a research team working on a new drug aimed at treating a rapidly spreading variant of a new viral infectious disease. The disease has been rapidly spreading across the world and the cases reported in the country are increasing. There is huge pressure on Dr. Srinivasan’s team to expedite the trials for the drug as there is significant market for it, and the company wants to get the first-mover advantage in the market. During a team meeting, some senior team members suggest some shortcut for expediting the clinical trials for the drug and for getting the requisite approvals. These include manipulating data to exclude some negative outcomes and selectively reporting positive results, foregoing the process of informed consent and using compounds already patented by a rival company, rather than developing one’s own component. Dr. Srinivasan is not comfortable taking such shortcuts, at the same time he realises meeting the targets is impossible without using these means. (a) What would you do in such a situation? (b) Examine your options and consequences in the light of the ethical questions involved. (c) How can data ethics and drug ethics save humanity at large in such a scenario?
Model answer
20 marks · 250-word limitA drug trial rests on two promises: the data are true and the participants consented. The proposed shortcuts break both, and using a rival's patented compounds adds infringement. In a fast-spreading outbreak the pressure is real, but a drug approved on manipulated data can harm the very patients it is meant to save.
- Exclude negative outcomes
- Report only positive results
- Skip informed consent
- Use rival's patented compounds
- Complete, honest trial data
- Valid informed consent
- Own compound or a licence
- More resources and early regulator engagement
(a) What I would do
- Refuse every shortcut: Reject data manipulation, selective reporting, bypassing consent and use of the rival's patented compounds, and have my objection recorded in the minutes.
- Escalate with a plan: Brief top management and the ethics committee on legal, safety and reputational risks, and present a realistic revised timeline.
- Accelerate lawfully: Seek more sites, staff and parallel work streams, and engage the regulator early on any expedited route available for serious unmet needs.
- License, don't copy: If the rival's compound is essential, negotiate a licence or collaboration.
- Last resort: If the company insists, decline to lead the work and use lawful whistle-blowing channels.
(b) Options and consequences in light of the ethical questions
| Option | Consequences |
|---|---|
| Adopt the shortcuts | Target met, but unsafe drug, harm to patients, rejection of approvals, legal liability and lasting loss of trust |
| Stay silent and let others decide | Complicity; moral responsibility remains |
| Resign quietly | Personal integrity kept, but risk to patients continues |
| Refuse, escalate and accelerate ethically | Some delay and pressure, but credible data, valid approval and a durable product |
- Truthfulness: Hiding adverse outcomes is deception of regulators, doctors and patients.
- Autonomy and dignity: Enrolling people without informed consent treats them merely as means, which Kant's humanity formula forbids.
- Consequences: A fast but unsafe drug can do more harm than the delay it avoids; first-mover profit cannot outweigh lives.
(c) How data ethics and drug ethics protect humanity
- Reliable evidence: Doctors and regulators worldwide act on published trial data; suppressed negative results mislead every future prescription.
- Consent as foundation: The Nuremberg Code (1947) and the Declaration of Helsinki (1964) made voluntary informed consent the basis of research on humans.
- Indian safeguards: The New Drugs and Clinical Trials Rules, 2019 and ICMR's National Ethical Guidelines (2017) require ethics committee approval and informed consent.
- Trust during outbreaks: Honest science sustains public confidence in drugs and vaccines when cooperation matters most.
- Fair innovation: Respecting patents rewards genuine research, while the Patents Act, 1970 itself provides compulsory licensing for public health needs.
In a spreading epidemic, a drug no one can trust saves no one. Dr. Srinivasan should refuse the shortcuts and lead an honest acceleration: truthful data, genuine consent and lawful use of others' inventions are not obstacles to beating the disease but the only way a cure truly helps humanity.
Read more — sources
- OfficialNew Drugs and Clinical Trials Rules, 2019 (Central Drugs Standard Control Organisation)
- OfficialICMR — National Ethical Guidelines for Biomedical and Health Research Involving Human Participants (2017)
- OfficialWorld Medical Association — Declaration of Helsinki (1964, as amended)
- OfficialThe Patents Act, 1970
Related questions from earlier years
More from GS Paper 4 (Ethics) 2024
Model answer by the EdiShorts editorial team. It is one well-argued treatment of the question, written to the official word limit — not an official UPSC answer key.